Gan & Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the commercialisation of bofanglutide injection in South Korea.

Roche has signed a new collaboration deal with C4 Therapeutics to jointly advance DACs research to introduce a new therapeutic modality for cancer.

Biomarkers are revolutionizing oncology drug development, driving modern precision medicine approaches, targeted clinical trial recruitment strategies, and critical decision-making.

Shionogi will use the money from BARDA to build an American antibiotic manufacturing site as the US looks to fight antimicrobial resistance.

Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten ...

The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.

The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.

Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for Hypercon technology.

Pharma trade bodies have warned of negative impacts from tariffs, while analysts point to geopolitical catalysts.

As healthcare accelerates toward data intensive innovation, mounting pressure on hospital networks is exposing an uncomfortable truth: many are not ready.

Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.

Otsuka Pharmaceutical is to fully acquire Transcend Therapeutics via its subsidiary Otsuka America for a potential ...